Immuneering raises $25mln in private placement for cancer drug development.

Immuneering Corporation has announced a private placement of securities, expected to raise approximately $25 million, to top-tier institutional and accredited investors. The company plans to use the funds to advance its clinical-stage oncology programs, including updated Overall Survival and Progression-Free Survival data from its Phase 2a trial of atebimetinib in first-line pancreatic cancer patients, to be released in the coming weeks.

Immuneering Corporation (NASDAQ: IMRX), a clinical-stage oncology company, has announced a private placement of securities, expected to raise approximately $25 million, to top-tier institutional and accredited investors. The company plans to use the funds to advance its clinical-stage oncology programs, including the upcoming release of updated Overall Survival (OS) and Progression-Free Survival (PFS) data from its Phase 2a trial of atebimetinib in first-line pancreatic cancer patients.

The private placement, which is expected to close around August 26, 2025, subject to customary conditions, involves the sale of 6,329,113 unregistered shares of Immuneering’s Class A common stock at $3.95 per share. Certain investors will also receive pre-funded warrants to purchase an additional 2,848,096 shares of Class A common stock, with an exercise price of $5.50 per share. The proceeds from this financing will support Immuneering’s ongoing efforts to bring atebimetinib, a Deep Cyclic Inhibitor of MEK in the MAPK pathway, to as many cancer patients as possible as quickly as possible.

The company has been generating strong interest from leading pharmaceutical companies and top-tier investors due to its exceptional 6-month overall survival data in first-line pancreatic cancer patients. In June, Immuneering reported a 94% OS observed at 6 months in first-line pancreatic cancer patients treated with atebimetinib in combination with mGnP, compared to a 67% OS in the pivotal study of standard of care GnP, which dropped to 50% by 8.5 months.

Immuneering is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors, which represent an important new way to keep cancer patients alive and help them thrive. The company’s lead product candidate, atebimetinib (IMM-1-104), is an oral, once-daily Deep Cyclic Inhibitor of MEK designed to improve durability and tolerability, and expand indications to include MAPK pathway-driven tumors such as most pancreatic cancers.

This private placement is part of Immuneering’s ongoing efforts to bring its innovative cancer therapies to market and improve patient outcomes. The company’s development pipeline also includes early-stage programs, and it is focused on keeping cancer patients alive through its cutting-edge approach to therapeutic intervention.

References:
[1] https://ir.immuneering.com/news-releases/news-release-details/immuneering-announces-25-million-private-placement
[2] https://investorshub.advfn.com/market-news/article/15090/immuneering-secures-25-million-in-private-placement-to-advance-cancer-drug-development